Effect of Supersaturated Oxygen (SSO2) on Left Ventricular Ejection Fraction (LVEF) in LAD STEMI Patients Post PCI in the Real World: Retrospective Comparison to Control Patients
American College of Cardiology Annual Scientific Session & Expo with World Congress of Cardiology, March 4-6, 2023, New Orleans, LA.
Abstract
Background: Studies have shown that intra-coronary supersaturated oxygen therapy (SSO2) post PCI significantly reduces infarct size in LAD STEMI patients, but data related to the temporal recovery of LVEF in the real world post FDA approval is scarce. Methods: Single-center retrospective cohort. We included STEMI patients aged 40-80 with proximal/mid-LAD infarct, symptom onset within 6 hours of presentation, without cardiogenic shock, and at least one month clinical/echo follow up. Absolute and change in echo LVEF at one and three months were compared between SSO2 and contemporaneous control patients. Results: 51 patients were included: n=14 received SSO2 and n=37 in the Control group. No significant difference was observed between groups in demographics, comorbidity, or baseline LVEF. There was a significant increase in LVEF at one month from baseline in the SSO2 group (15.4%) vs control (2%) (p=0.003). Results were consistent in a subgroup analysis at three months; 21% LVEF increase in SSO2 vs 5% in control (p<0.005). This was confirmed with two-way repeated measures ANOVA testing (p<0.001). Significantly fewer patients in the SSO2 group (0% versus 32%) had an LVEF <35% at 3 months (p<0.05). The clinical complication rate was lower for the SSO2 group (1/14) vs the Control group (13/37).Conclusion: Our results suggest that SSO2 is associated with significant and progressive LVEF recovery (absolute and change in LVEF) compared to the Control group at one and three months follow-up.